Due to the fact that the treatment of breast cancer depends significantly on the molecular markers present in the cancer, includingestrogen receptor (+), progesterone receptor (+) or erbB2 receptor (+), further investigation targeting triple-negative breast cancer(TNBC) subtypes may assist in elucidating the mechanisms of recurrence of TNBC and enable the identification of novel therapeuticstrategies for patients with TNBC [1]. The gene discussed is PGR; the disease is triple-negative breast carcinoma.